BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21917434)

  • 1. Impact of metabolic syndrome on clinical outcomes after new generation drug-eluting stent implantation: the 'obesity paradox' phenomenon is still apparent.
    Patsa C; Toutouzas K; Tsiamis E; Tsioufis C; Spanos A; Karanasos A; Michelongona A; Tousoulis D; Stefanadis C
    Nutr Metab Cardiovasc Dis; 2013 Apr; 23(4):307-13. PubMed ID: 21917434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
    Li Y; Han Y; Zhang L; Jing Q; Wang X; Yan G; Ma Y; Wang G; Wang S; Chen X; Yang L; Zhu G; Liu H; Jiang T
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1127-33. PubMed ID: 22945767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical outcomes between first-generation and second-generation drug-eluting stents in type 2 diabetic patients.
    Jeong HS; Cho JY; Kim EJ; Yu CW; Ahn CM; Park JH; Hong SJ; Lim DS
    Coron Artery Dis; 2013 Dec; 24(8):676-83. PubMed ID: 23994881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome does not impact long-term survival in patients with acute myocardial infarction after successful percutaneous coronary intervention with drug-eluting stents.
    Won KB; Kim BK; Chang HJ; Shin DH; Kim JS; Ko YG; Choi D; Ha JW; Hong MK; Jang Y
    Catheter Cardiovasc Interv; 2014 Apr; 83(5):713-20. PubMed ID: 23934969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
    Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
    EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical outcomes following drug-eluting stent implantation for unprotected distal trifurcation left main disease: the Milan-New Tokyo (MITO) registry.
    Ielasi A; Takagi K; Latib A; Basavarajaiah S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A
    Catheter Cardiovasc Interv; 2014 Mar; 83(4):530-8. PubMed ID: 23983065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.
    Magalhaes MA; Minha S; Chen F; Torguson R; Omar AF; Loh JP; Escarcega RO; Lipinski MJ; Baker NC; Kitabata H; Ota H; Suddath WO; Satler LF; Pichard AD; Waksman R
    Circ Cardiovasc Interv; 2014 Dec; 7(6):768-76. PubMed ID: 25466551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of diabetes mellitus on patients with unprotected left main coronary artery lesion disease treated with either percutaneous coronary intervention or coronary-artery bypass grafting.
    Luo Y; Yu X; Chen F; Du X; He J; Gao Y; Zhang X; Zhang Y; Ren X; Lv S; Ma C
    Coron Artery Dis; 2012 Aug; 23(5):322-9. PubMed ID: 22750912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative long-term efficacy and safety of drug-eluting stent versus coronary artery bypass grafting in ostial left main coronary artery disease: analysis of the MAIN-COMPARE registry.
    Lee SW; Kim SH; Kim SO; Han S; Kim YH; Park DW; Kang SJ; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):206-12. PubMed ID: 22234884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
    Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
    Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early beneficial effects of drug-eluting stents in vein grafts wane during long term follow-up: a case-control study.
    Pasceri V; Tarsia G; Niccoli G; Viceconte N; Porto I; Leone AM; Trani C; Speciale G; Lisanti P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1112-7. PubMed ID: 22422701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between body mass index and clinical outcomes after new-generation drug-eluting stent implantation: Korean multi-center registry data.
    Kim BG; Hong SJ; Kim BK; Ahn CM; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Atherosclerosis; 2018 Oct; 277():155-162. PubMed ID: 30216914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
    Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C
    Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Kersting S; Grumann T; Hummel J; Hauschke D; Bode C; Hehrlein C
    Crit Pathw Cardiol; 2012 Sep; 11(3):152-9. PubMed ID: 22825536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
    Miao Y; Yu-Jie Z; Zhi-Jian W; Dong-Mei S; Yu-Yang L; Ying-Xin Z; Fei G; Shi-Wei Y; De-An J
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):361-7. PubMed ID: 22419375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ad hoc percutaneous coronary intervention with drug-eluting stents in angina patients.
    Kim YH; Park DW; Ahn JM; Park GM; Cho YR; Lee JY; Kim WJ; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ;
    EuroIntervention; 2013 May; 9(1):110-7. PubMed ID: 23685299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial.
    Roguin A; Camenzind E; Kerner A; Beyar R; Boersma E; Mauri L; Steg PG; Wijns W
    JACC Cardiovasc Interv; 2017 Mar; 10(6):548-556. PubMed ID: 28335893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.